February 11, 2014
January 28, 2014
Dr. Arnaud Foussat at Immunotherapy Forum
Cellular Immunotherapy of chronic inflammation and autoimmunity using autologous antigen-specific T regulatory (Treg) cells
January 15, 2014
January 7, 2014
Treg: Regulatory T Cells and T Helper Cells
Antigen-specific Type 1 Treg cells
The technology developed by TxCell uses the immuno-modulatory properties of peripheral blood antigen-specific Type 1 regulatory T cells (Ag-Treg). This cell population has been co-discovered by the TxCell founder scientist in 1997 (link).
Type 1 Treg cells are naturally occurring blood cells specialized to induce tolerance against environmental foreign antigens taken up by inhalation, ingestion or contact and certain tissue specific self-antigens.
Type 1 Treg cells have been shown to prevent autoimmune and chronic inflammatory diseases in different experimental animal models such as colitis, arthritis, multiple sclerosis.
Type 1 Treg cells home preferentially to the sites of injury and control inflammation by:
(1) secreting natural immunosuppressive molecules such as Interleukin-10 (IL-10) and Interleukin-13 (IL-13),
(2) initiating cell-cell contact mediated suppression through surface molecules such as CTLA-4 and GITR and
(3) killing of myeloid cells via a Perforin/Granzyme B pathway.
These multiple mechanisms of action lead to inhibition of pro-inflammatory cell activation, proliferation and cytokine production (Figure 1).
Figure 1. Peripheral blood Type 1 Treg cells